Addis Ababa – 13 April 2018
Study launched as part of new Afri-KA-DIA Consortium will also assess diagnostic tools
A new study to find a safer, efficacious and more patient-friendly treatment and improved diagnostic tools for people living with visceral leishmaniasis (VL) has begun in eastern Africa, within the new Afri-KA-DIA consortium with funding from The European & Developing Countries Clinical Trials Partnership (EDCTP). The large-scale Phase III clinical trial seeks to assess the efficacy and safety of a combination of miltefosine and paromomycin in treating VL in eastern Africa.
Addis Ababa – 13 April 2018
Osaka, Japan and Geneva, Switzerland – 5 April 2018
Efforts funded by the Global Health Innovative Technology Fund for pre-clinical and phase I clinical studies
Takeda Pharmaceutical Co., Ltd. and DNDi today announced that they have signed an agreement to collaborate in conducting preclinical and phase I clinical studies on drug candidate compounds that had been discovered among the aminopyrazole compound class, aimed at developing an innovative drug for the treatment of visceral leishmaniasis (VL).
24-25 May 2018
Olawale Salami, Paediatric HIV Clinical Project Manager DNDi Africa – presentation of the LIVING study on treatment for paediatric HIV
Leishmaniasis Team, DNDi – presentation on PKDL in the Indian subcontinent
Jorge Alvar, Senior Leishmaniasis Advisor, DNDi – presentation on HIV-VL in East Africa
The Japanese pharmaceutical company Astellas Pharma Inc. is the eighth pharmaceutical company to join the Neglected Tropical Diseases Drug Discovery Booster, a global consortium launched in 2015 by DNDi to speed up the process and cut the cost of finding new treatments for leishmaniasis and Chagas disease.
Daiichi Sankyo RD Novare and DNDi are pleased to announce the financial support of the Japan Global Health Innovative Technology Fund to their new collaboration on natural products.
by Van den Kerkhof M, Mabille D, Chatelain E, Mowbray CE, Braillard S, Hendrickx S, Maes L, Caljon G.
International Journal for Parasitology: Drugs and Drug Resistance, April 2018
Geneva / Brentford / Dundee – 27 March 2018
The not-for-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) will collaborate with GlaxoSmithKline (GSK), and the University of Dundee Drug Discovery Unit (DDU), in a bid to discover new pre-clinical drug candidates targeting two parasitic neglected tropical diseases (NTDs), leishmaniasis and Chagas disease.
21-24 April 2018
Monique Wasunna, Director, DNDi Africa – presentation on visceral leishmaniasis in a session on Africa & Middle East
Medscape [14 March 2018]
“Terapia combinada mejora la tasa de cura de la leishmaniasis cutánea, según datos preliminares” – “Combination therapy improves cure rate of cutaneous leishmaniasis, according to preliminary data”
by Eberhardt E, Van den Kerkhof M, Bulté D, Mabille D, Van Bockstal L, Monnerat S, Alves F, Mbui J, Delputte P, Cos P, Hendrickx S, Maes L, Caljon G.
Journal of Molecular Diagnostics, March 2018
by Thompson AM, O’Connor PD, Marshall AJ, Blaser A, Yardley V, Maes L, Gupta S, Launay D, Braillard S, Chatelain E, Wan B, Franzblau SG, Ma Z, Cooper CB, and Denny WA.
Journal of Medicinal Chemistry, February 2018
7th Edition: Precision Global Health in the Digital Age
10-12 April 2018
Bernard Pécoul, Executive Director – plenary talk on emerging infectious diseases crisis
Digas Ngolo, Investigator Coordinator, DNDi Africa – parallel session on ehealth
21-23 March 2018
Jorge Alvar, Senior Leishmaniasis Advisor – presentation and panel discussion on leishmaniasis
by Olliaro P, Boni M, Carvalho EM, Chebli H, Cisse M, Diro E, Fernandes Cota G, Erber AC, Gadisa E, Handjani F, Khamesipour A, Llanos-Cuentas A, López Carvajal L, Grout L, Lmimouni BE, Mokni M, Nahzat MS, Ben Salah A, Ozbel Y, Pascale JM, Rizzo Molina N, Rode J, Romero G, Ruiz-Postigo JA, Gore Saravia N, Soto J, Uzun S, Mashayekhi V, Vélez ID, Vogt F, Zerpa O, Arana B.
PLoS Neglected Tropical Diseases, January 2018
1-4 March 2018
Buenos Aires, Argentina
Sergio Sosa-Estani, Head of Chagas, DNDi Latin America – presentation on Chagas disease
Byron Arana, Head of Cutaneous Leishmaniasis, DNDi – parallel symposium on cutaneous leishmaniasis
Graciela Diap, Paediatric HIV/HCV, DNDi, and Francisco Viegas Neves da Silva, Regional Policy Advocacy Consultant, DNDi Latin America – parallel symposium on hepatitis C
16-17 February 2018
Suman Rijal, Director of Regional Office, DNDi India – presentation on the elimination of leishmaniasis
Tidsskriftet [25 December 2017]
“Developing a vaccine for leishmaniasis: how biology shapes policy”
by Croft SL, Chatelain E, Barrett MP.
Emerging Topics in Life Sciences, December 2017
by Ibarra-Meneses AV, Mondal D, Alvar J, Moreno J, Carrillo E.
Scientific Reports, December 2017